Japan Cell Therapy Market - 2025-2033
Japan Cell Therapy Market: Industry Outlook
The Japan cell therapy market reached US$ 416.83 Million in 2024 and is expected to reach US$ 1,632.99 Million by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033.
The Japan cell therapy market stands out as a hub of innovation, supported by proactive government policies, streamlined regulatory pathways, and a robust academic research environment. Japan’s global leadership in induced pluripotent stem cell (iPSC) research—spearheaded by institutions like Kyoto University’s CiRA and RIKEN—continues to accelerate advancements in regenerative medicine. In 2025, the market growth is being fueled by the country’s rapidly aging population and rising burden of chronic and degenerative diseases such as Parkinson’s, heart failure, and certain cancers. Additionally, there’s increasing demand for personalized, cell-based therapies targeting oncology, neurology, and rare genetic disorders. Favorable regulatory initiatives like the Sakigake fast-track system are also enabling quicker approval and commercialization of novel therapies.
Japan Cell Therapy Market: Market Dynamics: Drivers & Restraints
Driver: Rise in the Prevalence of Cancers in Japan
The increasing cancer prevalence in Japan is driving the growth of the country's cell therapy market. Conventional treatments like chemotherapy and radiation have limitations, leading to a demand for personalized, targeted approaches. Cell therapies, particularly CAR-T and T-cell-based immunotherapies, harness the body's immune system to combat cancer. This has accelerated research, clinical trials, and regulatory support, making oncology a central focus for innovation and investment in Japan's cell therapy landscape.
For instance, Japan's cancer prevalence is projected to rise by 13.1% by 2050, primarily due to a 13.6% increase in female survivors. From 2040 onwards, females will overtake males in prevalence counts. The most prevalent cancer sites in 2050 are colorectal, female breast, prostate, lung, and stomach cancers, accounting for 66.4% of survivors. Males are expected to experience the highest absolute increases in prostate, lung, and malignant lymphoma cancers, while females are expected to experience the highest absolute increases in breast, colorectal, and corpus uteri cancers.
Hence, the rising cancer prevalence in Japan, particularly among females, will drive demand for innovative treatments like cell therapy. The dominance of breast, colorectal, and prostate cancers aligns with current targets of cell-based immunotherapies. From 2040, gender-focused cell therapy development is possible, and high survivor rates indicate a growing market for long-term, less invasive treatments.
Restraint: Dearth of Skilled Professionals
The cell therapy market in Japan faces a significant challenge due to a lack of skilled professionals. Despite Japan's strong academic infrastructure, there is a shortage of trained personnel capable of handling complex cell culture techniques, Good Manufacturing Practice compliance, and large-scale manufacturing processes. This talent gap hinders product development, delays clinical trial execution, and limits therapy scalability, affecting the market's ability to meet growing domestic and global demand.
Japan Cell Therapy Market: Segment Analysis
The Japan cell therapy market is segmented based on therapy type, cell type, source, application, and end user.
Therapy Type:
The autologous cell therapy from therapy type segment is expected to dominate the Japan cell therapy market with the market share of 54.55%
Autologous cell therapy is a treatment method where a patient's own cells are collected, modified, or expanded, and reintroduced into their body to treat diseases. This method reduces immune rejection risk and is widely used in Japan for regenerative medicine, oncology, and orthopedics, enhancing patient outcomes.
Japan's increasing demand for personalized, minimally invasive treatments is driving the growth of autologous cell therapy. The country's regulatory framework supports accelerated approval pathways for regenerative therapies, favoring autologous approaches due to lower immunogenic risk and ethical acceptability. The aging population and rising degenerative diseases like osteoarthritis and cardiovascular disorders make autologous therapies promising. The integration of advanced cell-processing technologies and hospital-based programs further enhances accessibility and growth.
For instance, in September 2024, Biostar Stem Cell Research Institute's affiliate hospital, Shinjuku Clinic, has been approved for Japanese post-production of a regenerative medical technology to treat Alzheimer's. The technology involves administering autologous fat-derived stem cells cultured with patented technology into the spinal cavity and intravenously.
Japan Cell Therapy Market: Competitive Landscape
The Japan cell therapy market features a strong mix of established pharmaceutical firms, innovative biotech startups, and renowned research institutions. Key players include Fujifilm Cellular Dynamics, Healios K.K., JCR Pharmaceuticals, RIKEN, Takara Bio, Nipro Corporation, Medinet Ltd., and CellSeed Inc. These companies are actively advancing regenerative medicine through iPSC-based research, immuno-cell therapies, and cell processing technologies.
Backed by Japan’s supportive regulatory environment and substantial R&D investment, these firms are driving commercialization of cutting-edge cell therapies across oncology, neurology, and rare disease areas, helping position Japan as a global leader in cell-based innovation.
The Japan cell therapy market reached US$ 416.83 Million in 2024 and is expected to reach US$ 1,632.99 Million by 2033, growing at a CAGR of 16.5% during the forecast period 2025-2033.
The Japan cell therapy market stands out as a hub of innovation, supported by proactive government policies, streamlined regulatory pathways, and a robust academic research environment. Japan’s global leadership in induced pluripotent stem cell (iPSC) research—spearheaded by institutions like Kyoto University’s CiRA and RIKEN—continues to accelerate advancements in regenerative medicine. In 2025, the market growth is being fueled by the country’s rapidly aging population and rising burden of chronic and degenerative diseases such as Parkinson’s, heart failure, and certain cancers. Additionally, there’s increasing demand for personalized, cell-based therapies targeting oncology, neurology, and rare genetic disorders. Favorable regulatory initiatives like the Sakigake fast-track system are also enabling quicker approval and commercialization of novel therapies.
Japan Cell Therapy Market: Market Dynamics: Drivers & Restraints
Driver: Rise in the Prevalence of Cancers in Japan
The increasing cancer prevalence in Japan is driving the growth of the country's cell therapy market. Conventional treatments like chemotherapy and radiation have limitations, leading to a demand for personalized, targeted approaches. Cell therapies, particularly CAR-T and T-cell-based immunotherapies, harness the body's immune system to combat cancer. This has accelerated research, clinical trials, and regulatory support, making oncology a central focus for innovation and investment in Japan's cell therapy landscape.
For instance, Japan's cancer prevalence is projected to rise by 13.1% by 2050, primarily due to a 13.6% increase in female survivors. From 2040 onwards, females will overtake males in prevalence counts. The most prevalent cancer sites in 2050 are colorectal, female breast, prostate, lung, and stomach cancers, accounting for 66.4% of survivors. Males are expected to experience the highest absolute increases in prostate, lung, and malignant lymphoma cancers, while females are expected to experience the highest absolute increases in breast, colorectal, and corpus uteri cancers.
Hence, the rising cancer prevalence in Japan, particularly among females, will drive demand for innovative treatments like cell therapy. The dominance of breast, colorectal, and prostate cancers aligns with current targets of cell-based immunotherapies. From 2040, gender-focused cell therapy development is possible, and high survivor rates indicate a growing market for long-term, less invasive treatments.
Restraint: Dearth of Skilled Professionals
The cell therapy market in Japan faces a significant challenge due to a lack of skilled professionals. Despite Japan's strong academic infrastructure, there is a shortage of trained personnel capable of handling complex cell culture techniques, Good Manufacturing Practice compliance, and large-scale manufacturing processes. This talent gap hinders product development, delays clinical trial execution, and limits therapy scalability, affecting the market's ability to meet growing domestic and global demand.
Japan Cell Therapy Market: Segment Analysis
The Japan cell therapy market is segmented based on therapy type, cell type, source, application, and end user.
Therapy Type:
The autologous cell therapy from therapy type segment is expected to dominate the Japan cell therapy market with the market share of 54.55%
Autologous cell therapy is a treatment method where a patient's own cells are collected, modified, or expanded, and reintroduced into their body to treat diseases. This method reduces immune rejection risk and is widely used in Japan for regenerative medicine, oncology, and orthopedics, enhancing patient outcomes.
Japan's increasing demand for personalized, minimally invasive treatments is driving the growth of autologous cell therapy. The country's regulatory framework supports accelerated approval pathways for regenerative therapies, favoring autologous approaches due to lower immunogenic risk and ethical acceptability. The aging population and rising degenerative diseases like osteoarthritis and cardiovascular disorders make autologous therapies promising. The integration of advanced cell-processing technologies and hospital-based programs further enhances accessibility and growth.
For instance, in September 2024, Biostar Stem Cell Research Institute's affiliate hospital, Shinjuku Clinic, has been approved for Japanese post-production of a regenerative medical technology to treat Alzheimer's. The technology involves administering autologous fat-derived stem cells cultured with patented technology into the spinal cavity and intravenously.
Japan Cell Therapy Market: Competitive Landscape
The Japan cell therapy market features a strong mix of established pharmaceutical firms, innovative biotech startups, and renowned research institutions. Key players include Fujifilm Cellular Dynamics, Healios K.K., JCR Pharmaceuticals, RIKEN, Takara Bio, Nipro Corporation, Medinet Ltd., and CellSeed Inc. These companies are actively advancing regenerative medicine through iPSC-based research, immuno-cell therapies, and cell processing technologies.
Backed by Japan’s supportive regulatory environment and substantial R&D investment, these firms are driving commercialization of cutting-edge cell therapies across oncology, neurology, and rare disease areas, helping position Japan as a global leader in cell-based innovation.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy Type
2.4. Snippet by Cell Type
2.5. Snippet by Source
2.6. Snippet by Application
2.7. Snippet by End User
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rise in the Prevalence of Cancers in Japan
3.1.1.2. Strong Government Support for Regenerative Medicine
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Dearth of Skilled Professionals
3.1.2.2. Complex Regulatory and Manufacturing Requirements
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Increasing Clinical Trials in Oncology and CNS Disorders
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Porter’s Five Force Analysis
4.6. Supply Chain Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.12. Pricing Analysis and Price Dynamics
4.13. Key Opinion Leaders
5. BY THERAPY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
5.1.2. Market Attractiveness Index, By Therapy Type
5.2. Autologous Cell Therapy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Allogeneic Cell Therapy
6. BY CELL TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
6.1.2. Market Attractiveness Index, By Cell Type
6.2. Stem Cells*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Hematopoietic Stem Cells (HSCs)
6.2.4. Mesenchymal Stem Cells (MSCs)
6.2.5. Induced Pluripotent Stem Cells (iPSCs)
6.3. Non-stem Cells
6.3.1. T-cells (including CAR-T)
6.3.2. Dendritic cells
6.3.3. NK (Natural Killer) cells
7. BY SOURCE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
7.1.2. Market Attractiveness Index, By Source
7.2. Bone Marrow*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Umbilical Cord Blood
7.4. Adipose Tissue
7.5. Peripheral Blood
7.6. Others
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiovascular Diseases
8.4. Neurological Disorders
8.5. Musculoskeletal Disorders
8.6. Autoimmune Diseases
8.7. Wound Healing
8.8. Others
9. BY END USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals & Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Academic & Research Institutes
9.4. Biopharmaceutical and Biotechnology Companies
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Fujifilm Cellular Dynamics, Inc*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Healios K.K.
11.3. JCR Pharmaceuticals Co. Ltd.
11.4. RIKEN
11.5. Takara Bio Inc
11.6. Nipro Corporation
11.7. Medinet Ltd.
11.8. CellSeed Inc.
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Therapy Type
2.4. Snippet by Cell Type
2.5. Snippet by Source
2.6. Snippet by Application
2.7. Snippet by End User
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rise in the Prevalence of Cancers in Japan
3.1.1.2. Strong Government Support for Regenerative Medicine
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. Dearth of Skilled Professionals
3.1.2.2. Complex Regulatory and Manufacturing Requirements
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Increasing Clinical Trials in Oncology and CNS Disorders
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established leaders with largest selling Brand
4.1.3. Market leaders with established Product
4.2. CXO Perspectives
4.3. Latest Developments and Breakthroughs
4.4. Case Studies/Ongoing Research
4.5. Porter’s Five Force Analysis
4.6. Supply Chain Analysis
4.7. Patent Analysis
4.8. SWOT Analysis
4.9. Unmet Needs and Gaps
4.10. Recommended Strategies for Market Entry and Expansion
4.11. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
4.12. Pricing Analysis and Price Dynamics
4.13. Key Opinion Leaders
5. BY THERAPY TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
5.1.2. Market Attractiveness Index, By Therapy Type
5.2. Autologous Cell Therapy*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Allogeneic Cell Therapy
6. BY CELL TYPE
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Type
6.1.2. Market Attractiveness Index, By Cell Type
6.2. Stem Cells*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Hematopoietic Stem Cells (HSCs)
6.2.4. Mesenchymal Stem Cells (MSCs)
6.2.5. Induced Pluripotent Stem Cells (iPSCs)
6.3. Non-stem Cells
6.3.1. T-cells (including CAR-T)
6.3.2. Dendritic cells
6.3.3. NK (Natural Killer) cells
7. BY SOURCE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Source
7.1.2. Market Attractiveness Index, By Source
7.2. Bone Marrow*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Umbilical Cord Blood
7.4. Adipose Tissue
7.5. Peripheral Blood
7.6. Others
8. BY APPLICATION
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiovascular Diseases
8.4. Neurological Disorders
8.5. Musculoskeletal Disorders
8.6. Autoimmune Diseases
8.7. Wound Healing
8.8. Others
9. BY END USER
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
9.1.2. Market Attractiveness Index, By End User
9.2. Hospitals & Clinics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Academic & Research Institutes
9.4. Biopharmaceutical and Biotechnology Companies
10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking
11. COMPANY PROFILES
11.1. Fujifilm Cellular Dynamics, Inc*
11.1.1. Company Overview
11.1.2. Product Portfolio
11.1.2.1. Product Description
11.1.2.2. Product Key Performance Indicators (KPIs)
11.1.2.3. Historic and Forecasted Product Sales
11.1.2.4. Product Sales Volume
11.1.3. Financial Overview
11.1.3.1. Company Revenue
11.1.3.2. Geographical Revenue Shares
11.1.3.3. Revenue Forecasts
11.1.4. Key Developments
11.1.4.1. Mergers & Acquisitions
11.1.4.2. Key Product Development Activities
11.1.4.3. Regulatory Approvals, etc.
11.1.5. SWOT Analysis
11.2. Healios K.K.
11.3. JCR Pharmaceuticals Co. Ltd.
11.4. RIKEN
11.5. Takara Bio Inc
11.6. Nipro Corporation
11.7. Medinet Ltd.
11.8. CellSeed Inc.
LIST NOT EXHAUSTIVE
12. ASSUMPTIONS AND RESEARCH METHODOLOGY
12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Techniques
12.4. Data Verification and Validation
13. APPENDIX
13.1. About Us and Services
13.2. Contact Us
LIST OF TABLES
Table 1 Japan Cell Therapy Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Japan Cell Therapy Market Value, By Cell Type, 2025, 2029 & 2033 (US$ Million)
Table 3 Japan Cell Therapy Market Value, By Source, 2025, 2029 & 2033 (US$ Million)
Table 4 Japan Cell Therapy Market Value, By Source, 2025, 2029 & 2033 (US$ Million)
Table 5 Japan Cell Therapy Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 6 Japan Cell Therapy Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Million)
Table 7 Japan Cell Therapy Market Value, By Therapy Type, 2022-2033 (US$ Million)
Table 8 Japan Cell Therapy Market Value, By Cell Type, 2025, 2029 & 2033 (US$ Million)
Table 9 Japan Cell Therapy Market Value, By Cell Type, 2022-2033 (US$ Million)
Table 10 Japan Cell Therapy Market Value, By Source, 2025, 2029 & 2033 (US$ Million)
Table 11 Japan Cell Therapy Market Value, By Source, 2022-2033 (US$ Million)
Table 12 Japan Cell Therapy Market Value, By Source, 2025, 2029 & 2033 (US$ Million)
Table 13 Japan Cell Therapy Market Value, By Source, 2022-2033 (US$ Million)
Table 14 Japan Cell Therapy Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 15 Japan Cell Therapy Market Value, By End User, 2022-2033 (US$ Million)
Table 16 Fujifilm Cellular Dynamics, Inc: Overview
Table 17 Fujifilm Cellular Dynamics, Inc: Product Portfolio
Table 18 Fujifilm Cellular Dynamics, Inc: Key Developments
Table 19 Healios K.K.: Overview
Table 20 Healios K.K.: Product Portfolio
Table 21: Healios K.K.: Key Developments
Table 22 JCR Pharmaceuticals Co. Ltd.: Overview
Table 23 JCR Pharmaceuticals Co. Ltd.: Product Portfolio
Table 24 JCR Pharmaceuticals Co. Ltd.: Key Developments
Table 25 RIKEN: Overview
Table 26 RIKEN: Product Portfolio
Table 27 RIKEN: Key Developments
Table 28 Takara Bio Inc: Overview
Table 29 Takara Bio Inc: Product Portfolio
Table 30 Takara Bio Inc: Key Developments
Table 31 Nipro Corporation: Overview
Table 32 Nipro Corporation: Product Portfolio
Table 33 Nipro Corporation: Key Developments
Table 34 Medinet Ltd.: Overview
Table 35 Medinet Ltd.: Product Portfolio
Table 36 Medinet Ltd.: Key Developments
Table 37 CellSeed Inc.: Overview
Table 38 CellSeed Inc.: Product Portfolio
Table 39 CellSeed Inc.: Key Developments
Table 1 Japan Cell Therapy Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Million)
Table 2 Japan Cell Therapy Market Value, By Cell Type, 2025, 2029 & 2033 (US$ Million)
Table 3 Japan Cell Therapy Market Value, By Source, 2025, 2029 & 2033 (US$ Million)
Table 4 Japan Cell Therapy Market Value, By Source, 2025, 2029 & 2033 (US$ Million)
Table 5 Japan Cell Therapy Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 6 Japan Cell Therapy Market Value, By Therapy Type, 2025, 2029 & 2033 (US$ Million)
Table 7 Japan Cell Therapy Market Value, By Therapy Type, 2022-2033 (US$ Million)
Table 8 Japan Cell Therapy Market Value, By Cell Type, 2025, 2029 & 2033 (US$ Million)
Table 9 Japan Cell Therapy Market Value, By Cell Type, 2022-2033 (US$ Million)
Table 10 Japan Cell Therapy Market Value, By Source, 2025, 2029 & 2033 (US$ Million)
Table 11 Japan Cell Therapy Market Value, By Source, 2022-2033 (US$ Million)
Table 12 Japan Cell Therapy Market Value, By Source, 2025, 2029 & 2033 (US$ Million)
Table 13 Japan Cell Therapy Market Value, By Source, 2022-2033 (US$ Million)
Table 14 Japan Cell Therapy Market Value, By End User, 2025, 2029 & 2033 (US$ Million)
Table 15 Japan Cell Therapy Market Value, By End User, 2022-2033 (US$ Million)
Table 16 Fujifilm Cellular Dynamics, Inc: Overview
Table 17 Fujifilm Cellular Dynamics, Inc: Product Portfolio
Table 18 Fujifilm Cellular Dynamics, Inc: Key Developments
Table 19 Healios K.K.: Overview
Table 20 Healios K.K.: Product Portfolio
Table 21: Healios K.K.: Key Developments
Table 22 JCR Pharmaceuticals Co. Ltd.: Overview
Table 23 JCR Pharmaceuticals Co. Ltd.: Product Portfolio
Table 24 JCR Pharmaceuticals Co. Ltd.: Key Developments
Table 25 RIKEN: Overview
Table 26 RIKEN: Product Portfolio
Table 27 RIKEN: Key Developments
Table 28 Takara Bio Inc: Overview
Table 29 Takara Bio Inc: Product Portfolio
Table 30 Takara Bio Inc: Key Developments
Table 31 Nipro Corporation: Overview
Table 32 Nipro Corporation: Product Portfolio
Table 33 Nipro Corporation: Key Developments
Table 34 Medinet Ltd.: Overview
Table 35 Medinet Ltd.: Product Portfolio
Table 36 Medinet Ltd.: Key Developments
Table 37 CellSeed Inc.: Overview
Table 38 CellSeed Inc.: Product Portfolio
Table 39 CellSeed Inc.: Key Developments
LIST OF FIGURES
Figure 1 Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 2 Japan Cell Therapy Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 3 Japan Cell Therapy Market Share, By Cell Type, 2024 & 2033 (%)
Figure 4 Japan Cell Therapy Market Share, By Source, 2024 & 2033 (%)
Figure 5 Japan Cell Therapy Market Share, By Source, 2024 & 2033 (%)
Figure 6 Japan Cell Therapy Market Share, By End User, 2024 & 2033 (%)
Figure 7 Japan Cell Therapy Market Y-o-Y Growth, By Therapy Type, 2023-2033 (%)
Figure 8 Autologous Cell Therapy Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 9 Allogeneic Cell Therapy Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 10 Japan Cell Therapy Market Y-o-Y Growth, By Cell Type, 2023-2033 (%)
Figure 11 Stem Cells Cell Type in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 12 Non-stem Cells Cell Type in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 13 Japan Cell Therapy Market Y-o-Y Growth, By Source, 2023-2033 (%)
Figure 14 Bone Marrow Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 15: Umbilical Cord Blood Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 16 Adipose Tissue Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 17 Peripheral Blood Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 18: Other Sources in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 19 Japan Cell Therapy Market Y-o-Y Growth, By Source, 2023-2033 (%)
Figure 20 Oncology Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 21 Cardiovascular Diseases Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 22 Neurological Disorders Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 23 Musculoskeletal Disorders Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 24 Autoimmune Diseases Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 25 Wound Healing Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 26 Other Sources in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 27 Japan Cell Therapy Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 28 Hospitals & Clinics End User in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 29 Academic & Research Institutes End User in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 30 Biopharmaceutical and Biotechnology Companies End User in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 31 Fujifilm Cellular Dynamics, Inc: Financials
Figure 32 Healios K.K.: Financials
Figure 33 JCR Pharmaceuticals Co. Ltd.: Financials
Figure 34 RIKEN: Financials
Figure 35: Takara Bio Inc: Financials
Figure 36 Nipro Corporation: Financials
Figure 37 Medinet Ltd.: Financials
Figure 38 CellSeed Inc.: Financials
Figure 1 Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 2 Japan Cell Therapy Market Share, By Therapy Type, 2024 & 2033 (%)
Figure 3 Japan Cell Therapy Market Share, By Cell Type, 2024 & 2033 (%)
Figure 4 Japan Cell Therapy Market Share, By Source, 2024 & 2033 (%)
Figure 5 Japan Cell Therapy Market Share, By Source, 2024 & 2033 (%)
Figure 6 Japan Cell Therapy Market Share, By End User, 2024 & 2033 (%)
Figure 7 Japan Cell Therapy Market Y-o-Y Growth, By Therapy Type, 2023-2033 (%)
Figure 8 Autologous Cell Therapy Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 9 Allogeneic Cell Therapy Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 10 Japan Cell Therapy Market Y-o-Y Growth, By Cell Type, 2023-2033 (%)
Figure 11 Stem Cells Cell Type in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 12 Non-stem Cells Cell Type in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 13 Japan Cell Therapy Market Y-o-Y Growth, By Source, 2023-2033 (%)
Figure 14 Bone Marrow Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 15: Umbilical Cord Blood Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 16 Adipose Tissue Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 17 Peripheral Blood Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 18: Other Sources in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 19 Japan Cell Therapy Market Y-o-Y Growth, By Source, 2023-2033 (%)
Figure 20 Oncology Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 21 Cardiovascular Diseases Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 22 Neurological Disorders Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 23 Musculoskeletal Disorders Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 24 Autoimmune Diseases Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 25 Wound Healing Source in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 26 Other Sources in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 27 Japan Cell Therapy Market Y-o-Y Growth, By End User, 2023-2033 (%)
Figure 28 Hospitals & Clinics End User in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 29 Academic & Research Institutes End User in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 30 Biopharmaceutical and Biotechnology Companies End User in Japan Cell Therapy Market Value, 2022-2033 (US$ Million)
Figure 31 Fujifilm Cellular Dynamics, Inc: Financials
Figure 32 Healios K.K.: Financials
Figure 33 JCR Pharmaceuticals Co. Ltd.: Financials
Figure 34 RIKEN: Financials
Figure 35: Takara Bio Inc: Financials
Figure 36 Nipro Corporation: Financials
Figure 37 Medinet Ltd.: Financials
Figure 38 CellSeed Inc.: Financials
